Non-Alcoholic Fatty Liver Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with, or are suspected to have, non-alcoholic fatty liver disease (NAFLD) or alcohol-related liver disease (ALD), based on at least one of the following:
- People who drink more than 210 grams of alcohol per week (men) or more than 140 grams per week (women)
- People who have type 2 diabetes
- People who have at least 2 of the following health factors: a body mass index (BMI) of 25 or higher; high blood pressure (either taking blood pressure medication, or with readings at or above certain levels); abnormal cholesterol or fat levels in the blood; or higher-than-normal ferritin levels (a protein measured in a blood test)
- People whose liver appears bright on an ultrasound scan, and who are not taking certain medications known to affect the liver (such as systemic corticosteroids, tamoxifen, amiodarone, or methotrexate)
- Note: The last three participating clinics are enrolling only people who drink above the alcohol limits listed above, and/or have type 2 diabetes managed with insulin and/or at least two other diabetes medications (confirm with trial site for exact proportions being enrolled)
- People who agree to have a blood sample taken at a local laboratory involved in the study
- People who are covered by a health insurance or medical care scheme
- People who are willing and able to provide written consent to participate
Who may not be able to join:
- People who are already receiving specialist care for a chronic liver condition
- People who are in poor health with a serious short-term prognosis, where screening would not be appropriate (confirm with trial site)
- People who have severe liver disease with complications such as confusion caused by liver failure, yellowing of the skin, fluid build-up in the abdomen, internal bleeding from swollen blood vessels, or kidney problems related to liver disease
- People who currently have an active infection
- People who are pregnant or breastfeeding
- People who are detained by a legal or government authority
- People who are admitted to a health or social care facility for a reason other than this research
- People who are under a legal protection order (confirm with trial site)
- People who are not able to give their consent to participate
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 02 41 73 58 10
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Sensitivity of the eLIFT test for advanced liver fibrosis; Sensitivity of the Fibrometer test for advanced liver fibrosis
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.